Investigator

Ovidiu Tatar

Postdoctoral Research Fellow · Douglas Hospital Research Center, McGill University, Psychiatry

OTOvidiu Tatar
Papers(3)
Emotional response to…Recent changes in cer…Are Canadian Women Pr…
Collaborators(7)
Zeev RosbergerRona Moss-MorrisPatricia ZhuEmily McBrideJo WallerLaura MarlowBen Haward
Institutions(5)
Centre Hospitalier De…McGill UniversityKing's College LondonUniversity College Lo…King's College London

Papers

Emotional response to testing positive for human papillomavirus at cervical cancer screening: a mixed method systematic review with meta-analysis

Tens-of-millions of women every year test positive for human papillomavirus (HPV) at routine cervical screening. We performed a mixed-methods systematic review using a results-based convergent design to provide the first comprehensive overview of emotional response to testing positive for HPV (HPV+). We mapped our findings using the cognitive behavioural framework. Six electronic databases were searched from inception to 09-Nov-2019 and 33 papers were included. Random-effects meta-analyses revealed that HPV+ women with abnormal or normal cytology displayed higher short-term anxiety than those with normal results (MD on State-Trait Anxiety Inventory = 7.6, 95% CI: 4.59-10.60 and MD = 6.33, CI: 1.31-11.35, respectively); there were no long-term differences. Psychological distress (general/sexual/test-specific) was higher in HPV+ women with abnormal cytology in the short-term and long-term (SMD = 0.68, CI: 0.32-1.03 and SMD = 0.42, CI: 0.05-0.80, respectively). Testing HPV+ was also related to disgust/shame, surprise and fear about cancer. Broadly, adverse response related to eight cognitive constructs (low control, confusion, cancer-related concerns, relationship concerns, sexual concerns, uncertainty, stigma, low trust) and six behavioural constructs (relationship problems, social impact, non-disclosure of results, idiosyncratic prevention, indirect clinical interaction, changes to sexual practice). Almost exclusive use of observational and qualitative designs limited inferences of causality and conclusions regarding clinical significance.

Recent changes in cervical cancer screening guidelines: U.S. women's willingness for HPV testing instead of Pap testing

Cervical cancer screening guidelines in the United States were revised in 2018 to include the option of primary human papillomavirus (HPV) testing. The transition to this screening method may face difficulties as Pap testing has been the primary screening modality in the United States. The objective of this study is to assess information, motivation, and behavioral skills associated with willingness to receive an HPV test instead of a Pap test among women. The sample included U.S. 812 women, ages 30 to 65 years. Participants completed an online survey in 2018. The Information, Motivation, and Behavioral Skills (IMB) model was used to measure predictors of willingness for HPV testing. The outcome variables were willingness to receive the HPV test instead of the Pap test, with and without time interval details. Logistic regression modeling was used with SAS 9.4. Over half of the sample (55%) were willing to receive the HPV test. For the information domain, HPV knowledge was significantly associated with willingness for HPV testing (OR = 1.08, 95%CI 1.04-1.13). Significant motivating factors included: positive attitudes, social norms, perceived benefits, worry about cervical cancer, and worry about abnormal HPV tests. For behavioral skills, women were significantly more willing to get the HPV test if a provider recommended it (OR = 2.43, 95%CI 1.53-3.87) and currently up-to-date on cervical cancer screening guidelines (OR = 1.52, 95%CI 1.52-2.26). Addressing barriers and facilitators to willingness to transition to primary HPV testing over Pap testing is needed as the United States has updated guidelines for cervical cancer screening.

Are Canadian Women Prepared for the Transition to Primary HPV Testing in Cervical Screening? A National Survey of Knowledge, Attitudes, and Beliefs

As Canadian provinces and territories prepare to transition to HPV-based primary screening for cervical cancer, failure to identify and address potential barriers to screening could hinder program implementation. We examined screening-eligible Canadians’ attitudes towards and knowledge of cervical screening. A nationally representative sample of screening-eligible Canadians (N = 3724) completed a web-based survey in the summer of 2022. Oversampling ensured that half of the sample were underscreened for cervical cancer (>3 years since previous screening or never screened). The participants completed validated scales of cervical cancer, HPV, and HPV test knowledge and HPV test and self-sampling attitudes and beliefs. Between-group differences (underscreened vs. adequately screened) were calculated for scales and items using independent sample t-tests or chi-square tests. The underscreened participants (n = 1871) demonstrated significantly lower knowledge of cervical cancer, HPV, and the HPV test. The adequately screened participants (n = 1853) scored higher on the Confidence and Worries subscales of the HPV Test Attitudes and Beliefs Scale. The underscreened participants scored higher on the Personal Barriers and Social Norms subscales. The underscreened participants also endorsed greater Autonomy conferred by self-sampling. Our findings suggest important differential patterns of knowledge, attitudes, and beliefs between the underscreened and adequately screened Canadians. These findings highlight the need to develop targeted communication strategies and promote patient-centered, tailored approaches in cervical screening programs.

42Works
3Papers
7Collaborators

Positions

2024–

Postdoctoral Research Fellow

Douglas Hospital Research Center, McGill University · Psychiatry

2019–

Research Associate (part time)

Lady Davis Institute for Medical Research: Montreal, QC, CA · Institute of Community & Family Psychiatry, Lady Davis Institute for Medical Research

2019–

Research Agent

Research Center-Centre Hospitalier de l'Université de Montréal (CRCHUM) · Addiction Psychiatry Research Unit

2017–

Research Associate

Lady Davis Institute for Medical Research · Institute of Community & Family Psychiatry

2015–

Clinical Research Assistant

Lady Davis Institute for Medical Research · Institute of Community & Family Psychiatry

2014–

Clinical Trial Analyst

Alphanumeric Systems Inc. · Clinical Trials

2013–

Research Assistant (Geriatrics, Pharmacology)

Centre hospitalier universitaire de Québec

2012–

Research Assistant

Lady Davis Institute for Medical Research · Geriatrics

Education

2025

PhD

Université de Montréal · Psychiatric Sciences and Addictology

2015

Master of Science

McGill University Faculty of Medicine · Experimental Medicine-Family Medicine

1995

Medical Doctor

Iuliu Hațieganu University of Medicine and Pharmacy · Medicine

Country

CA

Links & IDs
0000-0003-1886-6390ResearchGatePublons

Scopus: 57190742498

Researcher Id: U-5847-2017